ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 582,51
-0,61%
Dow Jones
38 834,86
0,15%
DAX
18 083,67
-0,22%
Brent Oil
84,915
0,15%
Bitcoin
64 982,14
-0,24%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) Actualités

NRIX Nurix Therapeutics Inc

18,2425
2,95 (19,31%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Nurix Therapeutics Inc NRIX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
2,95 19,31% 18,2425 06:00:07
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
16,38 15,34 18,8999 18,44 15,29
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/6/202413:02EDGAR2Form 8-K - Current report
16/6/202411:30GLOBENurix Therapeutics Presents Positive Results from Ongoing..
14/6/202400:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202401:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202422:06EDGAR2Form S-3ASR - Automatic shelf registration statement of..
10/6/202413:00GLOBENurix Therapeutics to Host a Webcast and Conference Call to..
06/6/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202400:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202422:58EDGAR2Form 144 - Report of proposed sale of securities
29/5/202413:00GLOBENurix Therapeutics to Participate in the Jefferies Global..
28/5/202413:00GLOBENurix Therapeutics Appoints Paula G. O’Connor, M.D., as..
21/5/202413:06EDGAR2Form 8-K - Current report
21/5/202401:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202401:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202422:00GLOBENurix Therapeutics Announces Board Chair Transition
14/5/202416:00GLOBENurix Therapeutics Announces Upcoming Oral Presentation of..
07/5/202413:00GLOBENurix Therapeutics to Participate in RBC Capital Markets..
17/4/202400:21GLOBENurix Therapeutics Announces Closing of Public Offering and..
12/4/202405:38GLOBENurix Therapeutics Announces Pricing of Upsized $175.0..
11/4/202422:00GLOBENurix Therapeutics Announces Proposed Public Offering
10/4/202413:00GLOBENurix Therapeutics Reports First Quarter Fiscal 2024..
09/4/202419:15GLOBENurix Therapeutics Reports First Clinical Evidence of CNS..
09/4/202413:00GLOBENurix Therapeutics Announces Extension of Strategic..
03/4/202413:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
02/4/202413:00GLOBENurix Therapeutics Announces Extension of Strategic..
25/3/202412:00GLOBENurix Therapeutics is Part of a Team of International..
20/3/202414:40GLOBENurix Presents the Discovery and Chemical Structure of..
11/3/202412:02EDGAR2Form 8-K - Current report
11/3/202412:00GLOBENurix Therapeutics Announces U.S. FDA Lifts Partial Clinical..
06/3/202422:00GLOBENurix Therapeutics to Participate in Upcoming Investor..
05/3/202422:30GLOBENurix Therapeutics Announces Presentations at the American..
17/2/202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
15/2/202422:51EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/2/202422:01EDGAR2Form 8-K - Current report
15/2/202422:00GLOBENurix Therapeutics Reports Fourth Quarter and Fiscal Year..
15/2/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202413:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202422:01GLOBENurix Therapeutics Announces Publication in the Journal..
31/1/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202400:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/1/202422:48DJNNurix Therapeutics Gets FDA Fast-Track Designation for..
16/1/202422:01GLOBENurix Therapeutics Receives U.S. FDA Fast Track Designation..
08/1/202413:03EDGAR2Form 8-K - Current report
08/1/202413:00GLOBENurix Therapeutics Outlines 2024 Strategic Priorities with..
02/1/202422:01GLOBENurix Therapeutics to Present at 42nd Annual J.P. Morgan..

Dernières Valeurs Consultées

NASDAQ
NRIX
Nurix Therapeutics
EU
8938T
8938T
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés